Status:
TERMINATED
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
Lead Sponsor:
GeneOne Life Science, Inc.
Conditions:
SARS-CoV 2
Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
Detailed Description
This Phase II randomized, placebo-controlled, double-blind study will assess whether topical GLS-1200 applied via nasal spray atomizer is well-tolerated and can reduce the incidence of confirmed SARS-...
Eligibility Criteria
Inclusion
- Age 18 or older
- Able to provide informed consent
- Able and willing to comply with study procedures
- Able and willing to utilize an approved form of pregnancy prevention for women of child bearing potential through to the end of treatment
Exclusion
- Know allergy to quinine, quinidine, or mefloquine
- Confirmed prior positive test for SARS-CoV-2
- Treatment within the past 2 weeks with chloroquine, hydroxychloroquine, or remdesivir
- Pregnancy or documentation of pregnancy by pre-treatment urine test or breast feeding or plans to become pregnant during the course of the study
Key Trial Info
Start Date :
June 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 10 2023
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT04408183
Start Date
June 10 2020
End Date
January 10 2023
Last Update
July 31 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Sinus and Nasal Specialists of Louisiana
Baton Rouge, Louisiana, United States, 70809
2
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
3
Conroe Willis Medical Reasearch
Conroe, Texas, United States, 77304